Welcome to our dedicated page for Jacobs Engr Group news (Ticker: J), a resource for investors and traders seeking the latest updates and insights on Jacobs Engr Group stock.
Jacobs Solutions Inc. provides engineering, consulting, design, program management and lifecycle services for public- and private-sector infrastructure and industry clients. Company news commonly covers quarterly results, backlog and cash-return actions, as well as contract awards in transportation, water, energy, environmental, life sciences, advanced manufacturing, and cities and places markets.
Recurring updates also include mobility and transit design work, power transmission and distribution frameworks, flood resilience and AI-enabled infrastructure tools such as Flood IQ, and consulting assignments for cities, utilities and government agencies.
Jacobs (NYSE:J) has been awarded the FBI Information Technology Supplies and Support Services 2nd Generation (ITSSS-2) Blanket Purchase Agreement (BPA). This competitive contract, with an $8 billion total ceiling value over eight years, will provide critical IT support to the FBI and the broader Department of Justice. Jacobs will deliver solutions in seven key areas: workplace services, business applications, delivery services, platform services, infrastructure services, emerging technologies, and other IT services.
This award builds on Jacobs' nearly two-decade-long collaboration with the FBI, reinforcing its position as a trusted provider of innovative IT solutions. The contract underscores Jacobs' commitment to enhancing the FBI's mission-critical operations through cutting-edge technologies.
Amentum, a global engineering and technology solutions provider, has announced a capital markets day on August 13, 2024 at 10:00 a.m. EDT at the New York Stock Exchange. The event will showcase Amentum's solutions and capabilities, focusing on the synergies and benefits expected from the previously announced spin-off of Jacobs's (NYSE: J) Critical Mission Solutions and parts of its Divergent Solutions business, including Cyber & Intelligence, which will merge with Amentum.
CEO John Heller and the executive leadership team will discuss Amentum's strategy and financial outlook. A live webcast and presentation materials will be available on Amentum's investor relations website before the event begins.
Jacobs (NYSE:J) has announced the election of Mary Jackson to its Board of Directors, effective upon the closing of the company's previously announced business separation or by January 15, 2025. Vice Admiral Jackson, a 32-year U.S. Navy veteran, brings extensive experience in strategic growth and operational efficiency.
Jackson's expertise includes infrastructure management, program governance, budgeting, supply chain management, and risk management. CEO Bob Pragada highlighted her knowledge of operational effectiveness, digital transformation, and innovation as valuable assets for Jacobs' evolution as a pure play infrastructure solutions provider.
Currently, Jackson serves on several boards, including Victory Capital Holdings and Custom Truck One Source. She holds a bachelor's degree in physics from the U.S. Naval Academy and a master's in engineering management from George Washington University.
Jacobs (NYSE: J) has filed a Form 10 with the SEC for the planned spin-off of its Critical Mission Solutions and portions of its Divergent Solutions business, including Cyber & Intelligence. The spin-off will merge with Amentum to create a leading, publicly traded global engineering and technology solutions provider. The transaction is expected to close in Q4 of fiscal year 2024, with the combined company to be known as Amentum Holdings, Inc.
The Form 10 provides detailed information about the separation, distribution, and merger, including important business and financial details. This filing is part of an iterative process, with additional information to be included in subsequent versions. Amentum plans to hold a Capital Markets Day, which will be webcast, with details to be announced later.
Jacobs (NYSE:J), a leading engineering and professional services firm, has announced its plans to release fiscal third quarter 2024 earnings results before the market opens on Tuesday, August 6, 2024. The company will host a conference call and webcast at 10:00 a.m. ET on the same day. During this call, management will present the company's results and discuss current operating trends. Investors and interested parties can access the webcast and accompanying presentation slides through the company's website at jacobs.com.
Jacobs (NYSE: J) has announced a quarterly cash dividend of $0.29 per share, approved by its Board of Directors. This dividend will be distributed on August 23, 2024, to shareholders recorded by the close of business on July 26, 2024. This announcement reflects the company's commitment to providing consistent returns to its shareholders.
Jacobs (NYSE:J) has been chosen as the Owner's Representative for the Omaha Streetcar Authority's project in Nebraska's largest city, Omaha. The streetcar will create a three-mile loop with over 15 stops, connecting downtown and midtown areas, enhancing economic and environmental outcomes.
Jacobs' role involves design review, delivery oversight, and budget and schedule management. The project aims to reduce congestion and parking issues, while linking key areas such as medical facilities, universities, and cultural centers. It is projected to generate $12.1 billion in annual economic activity and $13 million in safety benefits over 20 years.
The electric, exhaust-free streetcars will have twice the lifespan of buses or cars, promoting sustainability. Jacobs' extensive experience in program management positions them as a key player in this transformative urban development initiative.
Jacobs (NYSE:J) is collaborating with Uisce Éireann, formerly Irish Water, to develop Ireland's Water Services Strategic Plan (WSSP) 2050. This initiative aims to ensure a resilient and sustainable water supply over the next 25 years. The draft WSSP outlines objectives and actions to address challenges such as climate change, population growth, and aging infrastructure. The project is part of the Multi Supplier Framework for Engineering Design Services and is expected to run for about two years. Public consultation on the draft WSSP is open until July 16, 2024. Jacobs' experience in global water utility projects supports Uisce Éireann in planning for future uncertainties.
Jacobs (NYSE:J) has been awarded a program management and consultancy contract for King County's South Treatment Plant Facility Program in Renton, Washington. The 12-year contract, worth over $800 million, aims to enhance water quality and system resiliency for nearly two million people in Seattle and the central Puget Sound region. Jacobs will oversee the project from initiation through design, construction, and commissioning. The facility currently treats up to 115 million gallons of wastewater daily during wet weather and includes an on-site educational program and a 1.5-acre demonstration farm. Jacobs' selection builds on a long-standing relationship with King County, having previously managed projects like the award-winning Georgetown Wet Weather Treatment Station and the Brightwater Treatment Plant.
Jacobs (NYSE:J) has been selected by FUJIFILM Diosynth Biotechnologies to support a $1.2 billion expansion of its large-scale biologics manufacturing site in Holly Springs, North Carolina. Initially chosen for the site's construction commencing in 2021, Jacobs will now provide engineering, procurement, and construction management for the expansion. This project will add 8 x 20,000-liter cell culture bioreactors and approximately 400,000 square feet of manufacturing space by 2028. The first phase of construction is expected to complete by 2025, making it one of the largest cell culture contract manufacturing facilities in North America. The site will enhance FUJIFILM Diosynth Biotechnologies' capacity for biologic therapeutics and medicines, offering comprehensive drug substance manufacturing, automated fill-finish, assembly, packaging, and labeling services for global biopharmaceutical clients.